Time of care and its impact in the evolution of laryngeal cancer

Main Article Content

Irma Yolanda Castillo-López http://orcid.org/0000-0002-6381-1367
Luis Humberto Govea-Camacho http://orcid.org/0000-0002-3559-3286
Yasmin Graciela Gutiérrez-Gallo http://orcid.org/0000-0003-4816-4066
Julio César Palacios López http://orcid.org/0000-0002-6585-5718

Keywords

Laryngeal Neoplasms, Survival, Outcome Assessment, Clinical Protocols

Abstract

Background: Laryngeal carcinoma is the 22nd most common cause of cancer in men worldwide and the second most common head and neck malignancy. The care of these patients is multidisciplinary. Factors such as tumor stage and initiation of treatment 60 days after diagnosis have been associated with worse survival.


Objective: To know the overall time of care in laryngeal cancer and its impact on the outcome of patients in a tertiary health center.


Material and methods: In July 2020, a retrospective study was carried out of 173 patients with laryngeal cancer diagnosed in the Department of Otorhinolaryngology from January 2014 to December 2018. Odds ratio and Fisher’s exact test were calculated with a p value of 0.05.


Results: 2 out of 77 patients started treatment at the recommended time. The total attention time (TAT) was 246 ± 159 days. 56% of the patients were still alive, 43% diseasefree and 10% with progression. Control of the disease was achieved in 69% of early tumors and only 26% in advanced ones.


Conclusions: The overall time of care impacts on the health status, affecting survival and control of disease. The stage of the tumor at the time of diagnosis is a decisive prognosis factor. Strategies towards multidisciplinary management and early detection in primary care should be created.

Abstract 75 | PDF (Spanish) Downloads 70

References

 

Nocini R, Molteni G, Mattiuzzi C, Lippi G. Updates on larynx cancer epidemiology. Chinese J Cancer Res. 2020;32(1):18- 25. doi: 10.21147/j.issn.1000-9604.2020.01.0.

 

Sierra MS, Soerjomataram I, Antoni S, Laversanne M, Piñeros M, de Vries E, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016;44(8):S23-42. doi: 10.1016/j.canep.2016.07.013.

 

Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. doi: 10.1245/s10434-010-0985-4.

 

National Cancer Institute. Cancer Stat Facts: Laryngeal Cancer. 5-year relative survival rates, 2012-2018. Disponible en: https://seer.cancer.gov/statfacts/html/laryn.html.

 

Bradford CR, Ferlito A, Devaney KO, Mäkitie AA, Rinaldo A. Prognostic factors in laryngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2020;5(1):74-81. doi: 10.1002/ lio2.353.

 

Wilkie MD, Lightbody KA, Pinto R, Tandon S, Jones TM, Lancaster J. Prognostic implications of pathologically determined tumour volume in glottic carcinomas treated by transoral laser microsurgery. Clin Otolaryngol. 2015;40(6):610-5. doi: 10.1111/ coa.12421.

 

Harris AT, Tanyi AA, Hart RD, Trites J, Rigby MH, Lancaster J, et al. Transoral laser surgery for laryngeal carcinoma: Has Steiner achieved a genuine paradigm shift in oncological surgery? Ann R Coll Surg Engl. 2018;100(1):2-5. doi: 10.1308/ rcsann.2017.0190.

 

Taylor SM, Kerr P, Fung K, Aneeshkumar MK, Wilke D, Jiang Y, et al. Treatment of T1b glottic SCC: Laser vs. Radiationa Canadian multicenter study. J Otolaryngol - Head Neck Surg. 2013;42:1. doi: 10.1186/1916-0216-42-22.

 

Elicin O, Giger R. Comparison of current surgical and non-surgical treatment strategies for early and locally advanced stage glottic laryngeal cancer and their outcome. Cancers (Basel). 2020;12(3):1-20. doi: 10.3390/cancers12030732.

 

Chen MM, Harris JP, Orosco RK, Sirjani D, Hara W, Divi V. Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. Otolaryngol - Head Neck Surg (United States). 2018;158(6):1051-6. doi: 10.1177/0194599817751679.

 

González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Reports Pract Oncol Radiother. 2015;20(5):328-39. doi: 10.1016/j.rpor.2015.05.010.

 

Liao DZ, Schlecht NF, Rosenblatt G, Kinkhabwala CM, Leonard JA, Ference RS, et al. Association of Delayed Time to Treatment Initiation with Overall Survival and Recurrence among Patients with Head and Neck Squamous Cell Carcinoma in an Underserved Urban Population. JAMA Otolaryngol - Head Neck Surg. 2019;145(11):1001-9. doi: 10.1001/ jamaoto.2019.2414.

 

Misono S, Marmor S, Yueh B, Virnig BA. Treatment and survival in 10,429 patients with localized laryngeal cancer: A population-based analysis. Cancer. 2014;120(12):1810-7.

 

Acosta-Huerta A, Aguilar-Rojo S, Lugo-Machado JA. Frecuencia, aspectos clínicos y factores asociados al cáncer de laringe. Acta de Otorrinolaringología & Cirugía de Cabeza y Cuello. 2017;45(4):240-246.

 

Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116(9 SUPPL. 2):1-13.

 

Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

 

Castillo-López IY, Govea-Camacho LH, Sánchez-Robles EE, Palacios-López JC. Caracterización clínico-patológica del cáncer de laringe en la población mexicana. Rev Med Inst Mex Seguro Soc. 2021;59(1):27-33. doi: 10.24875/RMIMSS. M21000049.

 

Herrera-Gómez Á, Villavicencio-Valencia V, Rascón-Ortiz M, Luna-Ortiz K. Demografía del cáncer laríngeo en el Instituto Nacional de Cancerología. Cir Cir. 2009;77(5):353-7.

 

Granados M, Luna-Ortiz K, Campos E, Lavin A. Cáncer de la Laringe: Nuevas Tendencias. Cancerologia. 2007;2:55-66.

 

Luna-Ortiz K, Villavicencio-Valencia V, Saucedo-Ramírez OJ, Rascón-Ortiz M. Cáncer de laringe en pacientes menores de 40 años. Cir Cir. 2006;74(4):225-9.

 

Ciolofan MS, Vlăescu AN, Mogoantă C-A, Ioniță E, Ioniță I, Căpitănescu AN, et al. Clinical, Histological and Immuno-histochemical Evaluation of Larynx Cancer. Curr Heal Sci J. 2017;43(4):367-75. doi: 10.12865/CHSJ.43.04.14.

 

Morse E, Fujiwara RJT, Judson B, Mehra S. Treatment delays in laryngeal squamous cell carcinoma: A national cancer database analysis. Laryngoscope. 2018;128(12):2751-8. doi: 10.1002/lary.27247.

 

Graboyes EM, Hughes-Halbert C. Delivering Timely Head and Neck Cancer Care to an Underserved Urban Population-Better Late Than Never, but Never Late Is Better. JAMA Otolaryngol Head Neck Surg. 2019;145(11):1010-1. doi: 10.1001/ jamaoto.2019.2432.

 

Salvador-Coloma C, Cohen E. Multidisciplinary care of laryngeal cancer. J Oncol Pract. 2016;12(8):717-24. doi: 10.1200/ JOP.2016.014225.

 

Laccourreye O, Marret G, Giraud P. A vicious enemy in head and neck oncology: Delay! Eur Ann Otorhinolaryngol Head Neck Dis. 2019;136(2):61-2. doi:10.1016/j.anorl.2018.11.002.